GlassScriptPhysician profile
Sonoo K Advani
NPI 1982669123
$34,202.94
in general payments reported to CMS, 2019-2025
34 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $11K · 2021: $6,363 · 2022: $209 · 2023: $704 · 2024: $1,078 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $55.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.65 |
| Education | $55.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,103.14 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $9,455.91 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $872.71 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $850.33 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $439.74 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $189.78 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $122.38 | 2021-2025 | Unithroid |
| Esperion Therapeutics, INC. | $115.68 | 2021 | |
| Medtronic, INC. | $95.89 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $85.05 | 2020-2024 | Freestyle Libre 3 |
| Abbvie INC. | $84.01 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $79.17 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $72.71 | 2023-2025 | Omnipod |
| Alvogen INC | $67.18 | 2024-2025 | Teriparatide |
| Azurity Pharmaceuticals, INC. | $51.75 | 2023 | Adthyza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $48.48 | 2025 | NP Thyroid 60 |
| Neurocrine Biosciences, INC. | $46.86 | 2025 | |
| Medtronic Minimed, INC. | $42.45 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $39.86 | 2020-2023 | |
| Sequel Med Tech, LLC | $34.24 | 2025 | Twiist |
| Zealand Pharma US, INC. | $34.15 | 2021-2022 | |
| Radius Health, INC. | $34.05 | 2025 | Tymlos |
| Amarin Pharma, INC. | $29.23 | 2020 | |
| Kyowa Kirin, INC. | $27.74 | 2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $27.34 | 2022-2025 | Recorlev |
| Beta Bionics, INC. | $26.86 | 2023 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $26.05 | 2020-2021 | |
| Ibsa Pharma INC. | $18.98 | 2025 | Tirosint, Licart, Flector |
| Nestle Healthcare Nutrition INC. | $15.40 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2022 | |
| Vistapharm, INC. | $14.58 | 2021 | |
| Horizon Therapeutics Plc | $12.67 | 2022 | |
| Becton, Dickinson and Company | $11.91 | 2020 | |
| Endo Pharmaceuticals INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonoo Advani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.